| Stereochemistry | RACEMIC |
| Molecular Formula | C16H21N.C4H6O4 |
| Molecular Weight | 345.4327 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.C1CN(C1)C2CCCC\C2=C/C3=CC=CC=C3
InChI
InChIKey=IEXXCIWKNWOEKZ-GVYCEHEKSA-N
InChI=1S/C16H21N.C4H6O4/c1-2-7-14(8-3-1)13-15-9-4-5-10-16(15)17-11-6-12-17;5-3(6)1-2-4(7)8/h1-3,7-8,13,16H,4-6,9-12H2;1-2H2,(H,5,6)(H,7,8)/b15-13+;
| Molecular Formula | C4H6O4 |
| Molecular Weight | 118.088 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H21N |
| Molecular Weight | 227.3446 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Optical Activity | ( + / - ) |
Tazadolene was developed as a novel non-opioid analgesic with antidepressant properties. Experiments on rodents have revealed that unique analgesia properties of tazadolene was due to the ability of this compound to activate both serotonergic and alpha 2 adrenergic antinociceptive systems. Information about the current use of this drug is not available.
